CEL-SCI CORP

NYSE: CVM (Cel-Sci Corporation)

Kemas kini terakhir: semalam, 11:29PM

1.21

-0.26 (-17.69%)

Penutupan Terdahulu 1.47
Jumlah Dagangan 879,800
Purata Dagangan (3B) 218,748
Modal Pasaran 21,282,676
Harga / Buku (P/B) 2.22
Julat 52 Minggu
0.890 (-26%) — 7.80 (544%)
Tarikh Pendapatan 12 Feb 2026
EPS Cair (TTM) -1.59
Jumlah Hutang/Ekuiti (D/E MRQ) 72.10%
Nisbah Semasa (MRQ) 1.48
Aliran Tunai Operasi (OCF TTM) -16.75 M
Aliran Tunai Bebas Leveraj (LFCF TTM) -8.91 M
Pulangan Atas Aset (ROA TTM) -66.82%
Pulangan Atas Ekuiti (ROE TTM) -252.53%

AISkor Stockmoo

-3.7
Pulangan di bawah kos modalnya. Pulangan atas modal menurun. info
Hutang rendah. Keuntungan lemah. Aliran tunai negatif. info
Daripada penilaian laporan AI Insight kami tentang pulangan dijangka berbanding risiko. info NA
Penilaian Relatif info NA
Pertumbuhan Tersirat info NA
Sejarah Penilaian info NA
Nilai Pegangan info NA
Premium Risiko info NA
Penilaian Pasaran info NA
Aliran menurun sepanjang tahun lalu. Jauh di bawah paras tertinggi 52 minggu. info
Aliran menurun, tetapi purata bergeraknya telah mendatar. Harga hampir dengan purata itu. Jatuh di bawah purata itu dengan dagangan tinggi. info
Daripada analisis teknikal AI kami terhadap carta. info NA
Corak Lilin info NA
Tiada harga sasaran terkini, jadi berdasarkan arah semakan harga sasaran. info
Sentimen Pegangan info NA
Sentimen Berita info NA
Institusi bersih -0.25% daripada saham dalam pemfailan 13F terkini: 22 pemegang menambah, 8 mengurang (suku berakhir 30 Sep 2026). info
Aktiviti Orang Dalam info NA
Persekitaran pasaran berhati-hati. info
Sektor ketinggalan berbanding pasaran.
Tonggak-tonggak sependapat, jadi skor diperkukuh.
Perolehan sesaham meningkat setiap tahun. Mencatat kerugian dalam tahun-tahun kebelakangan. info
Di bawah garis aliran jangka sederhana. info
Harga rendah berbanding purata 52 minggunya. Turun dalam tempoh 5 tahun. info
Aliran turun bagi ketiga-tiga tempoh. Momentum jangka pendek menurun. info
Harga hampir dengan paras sokongan. info
Skor Akhir -3.67
Tunjuk semua

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Biotechnology (US) Bercampur Menaik
Biotechnology (Global) Bercampur Menaik
Stok Cel-Sci Corporation - -

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B Skor
CVM 21 M - - 2.22 -3.7
CYBN 359 M - - - 0.0
NRXS 60 M - - 18.58 -1.2
NHWK 20 M - - 0.260 0.0
AEON 10 M - - - -3.3
TOVX 6 M - 0.099 0.610 -2.7

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research, development, and manufacturing of immune systems for the treatment of cancer and other diseases. The company's lead investigational immunotherapy is Multikine, a Leukocyte Interleukin injection, which has completed a pivotal Phase 3 clinical trial for patients, who are diagnosed with locally advanced primary squamous cell carcinoma of the head and neck. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company is developing CEL-2000 and CEL-4000 which are LEAPS based product candidates for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.

Sektor Healthcare
Industri Biotechnology
% Dimiliki oleh Orang Dalam 3.71%
% Dimiliki oleh Institusi 14.60%

Pemilikan

Nama Tarikh Syer Dipegang
Mai Capital Management 30 Sep 2026 109,280

Tiada data dalam julat masa ini.

Institusi

Pemilikan institusi: 12.94%

Kedudukan Pemegang Saham
Bertambah 22 196,419
Berkurang 8 208,017
Baharu 7 29,620
Dijual habis 3 62,567

Pemfailan SEC 13F melalui Nasdaq, pemfailan terkini hingga 30 Sep 2026. Pemfailan tiba sehingga 45 hari selepas setiap suku.

2 Positif 0 Negatif 0 Neutral
Tarikh Jenis Butiran
20 Nov 2026 Yahoo Finance CEL-SCI’s Multikine® Receives Saudi FDA NADR Designation, Accelerating Potential Commercial Launch
VIENNA, Va., November 20, 2026--CEL-SCI’s Multikine receives Saudi FDA NADR Designation, accelerating potential commercial launch.
10 Nov 2026 Yahoo Finance CEL-SCI’s Dr. Eyal Talor Receives Second International Keynote Invitation on Multikine Head and Neck Cancer Research
VIENNA, Va., November 10, 2026--CEL-SCI’s Dr. Eyal Talor receives second international keynote invitation on Multikine head and neck cancer research.
29 Oct 2026 Yahoo Finance CEL-SCI reports 73.4% five-year survival in Multikine Phase 3 patient analysis
CEL-SCI Corporation CEO Geert Kersten joined Steve Darling from Proactive to discuss new tumor-response and safety analyses from the company’s completed Phase 3 study of Multikine (Leukocyte Interleukin, Injection), an investigational immunotherapy for head and neck cancer. The findings were…
26 Oct 2026 Yahoo Finance CEL-SCI Presents New Phase 3 Multikine® Data at World Congress: Pre-Surgical Biomarkers Identify Head & Neck Cancer Patients Achieving 73% 5-Year Survival
VIENNA, Va,, October 26, 2026--CEL-SCI presents Phase 3 Multikine data at World Congress: Pre-Surgical Biomarkers Identify Head & Neck Cancer Patients Achieving 73% 5-Year Survival.
15 Sep 2026 Yahoo Finance CEL-SCI Invited to Deliver Keynote Address on Multikine at 6th World Congress on Otology, Rhinology and Laryngology
VIENNA, Va., September 15, 2026--CEL-SCI invited to deliver keynote address on Multikine at 6th World Congress on Otology, Rhinology and Laryngology.

Persediaan Teknikal Sederhana

Susunan aliran
Kecerunan
Kemasukan
Dagangan
Aliran menurun, tetapi purata bergeraknya telah mendatar. Harga hampir dengan purata itu. Jatuh di bawah purata itu dengan dagangan tinggi.
Sokongan terdekat: 1.08 – 1.40 · paras kukuh
Rintangan terdekat: 1.31 – 1.65 · paras kukuh · kerap diuji, mungkin pecah

AI Analisis Teknikal

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Risiko / Ganjaran
TP1:
TP2:

Kerugian hingga SL berbanding keuntungan hingga setiap sasaran, dari EP. Nisbah 2 atau lebih biasanya dicari.

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2026 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda